Who is affected by this change?

This affects Independence Blue Cross Oncology, Hematology providers on Medicare Advantage plans.

When does this change take effect?

This change is effective Apr 21, 2025.

Back to dashboard

Medicare AdvantageCoverageMedium impact

MA08.175, Nogapendekin alfa inbakicept-pmln (Anktiva®)

Independence Blue Cross·Oncology, Hematology·Pharmacy

Effective date

Apr 21, 2025

We identified it

Jun 19, 2026

Days to comply

—

Summary

A new Medicare Advantage policy MA08.175 has been created for Nogapendekin alfa inbakicept-pmln (Anktiva®), a pharmaceutical product. This establishes coverage and billing guidelines for this medication under Medicare Advantage plans.

Action Required

Action needed

By April 21, 2025: Billing team should review the full policy details at the provided URL to understand coverage criteria, prior authorization requirements, and billing procedures for Nogapendekin alfa inbakicept-pmln (Anktiva®). Update billing system and staff training materials accordingly once full policy content is available.

Related policy hubs

Independence Blue Cross policies Oncology Hematology